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Abstract: Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long 
term  complications  in  Chronic  Lymphocytic  Leukemia  (CLL)  and  Waldenström 
Macroglobulinemia (WM) patients. Although disease
role  in  leukemogenesis  there  is  great  concern  that  therapy  may  further  increase  the  risk  of 
developing these devastating complications. 
Nucleoside analogs (NA) and alkylating agents are considered  appropriate agents in the treatment 
of  both  CLL  and  WM  patients.  Prolonged 
incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, 
leads to speculation that their therapeutic use might be responsible for an increased incidence of 
second cancer  especially when combined with other DNA damaging agents like alkylating agents. 
In this review the published studies considering the occurrence of secondary MDS and AML in 
CLL  and  WM  patients  are  reported  and  the  potential  role  of  chemotherapeutic  agent
leukemogenesis is discussed. 
 
Introduction:  Advances  in  the  treatment  of  Chronic 
Lymphocytic  Leukemia  (CLL)  and  Waldenström 
Macroglobulinemia  (WM)  have  resulted  in  higher 
response  rates  and  more  durable  remissions. 
Chemoimmunotherapy has become the standard of care 
and  the  addition  of  rituximab  to  combination 
chemotherapy is associated with improved outcomes.
As a result, the number of cancer survivors is rapidly 
growing and the late toxicities of treatment particularly 
therapy-related  myeloid  neoplasms  (t
become a more important concern.  
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myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long 
term  complications  in  Chronic  Lymphocytic  Leukemia  (CLL)  and  Waldenström 
Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial 
esis  there  is  great  concern  that  therapy  may  further  increase  the  risk  of 
developing these devastating complications.  
Nucleoside analogs (NA) and alkylating agents are considered  appropriate agents in the treatment 
of  both  CLL  and  WM  patients.  Prolonged  immunosuppression  related  to  NA  therapy  and  the 
incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, 
leads to speculation that their therapeutic use might be responsible for an increased incidence of 
especially when combined with other DNA damaging agents like alkylating agents. 
In this review the published studies considering the occurrence of secondary MDS and AML in 
CLL  and  WM  patients  are  reported  and  the  potential  role  of  chemotherapeutic  agent
Advances  in  the  treatment  of  Chronic 
Lymphocytic  Leukemia  (CLL)  and  Waldenström 
(WM)  have  resulted  in  higher 
response  rates  and  more  durable  remissions. 
Chemoimmunotherapy has become the standard of care 
and  the  addition  of  rituximab  to  combination 
chemotherapy is associated with improved outcomes.
1-5 
r survivors is rapidly 
growing and the late toxicities of treatment particularly 
related  myeloid  neoplasms  (t-MN)  have 
Some authors have reported an increasing incidence 
of  these  late  complications  over  the  years
due  to  the  better  diagnostic  criteria  employed, 
increased  age  of  population  and    widespread  and 
successful use of drug combination in cancer patients.
A  comprehensive  review  of  reported 
myelodysplasia  and  acute  myeloid  leukemia 
(MDS/AML)  rates  concluded  that  up  to  10%  of 
patients treated for indolent non-Hodgkin’s lymphoma 
(NHL)  using  either  conventional  dose  alkylating 
agents-based  regimens  or  high-dose  therapy  develop 
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Some authors have reported an increasing incidence 
of  these  late  complications  over  the  years
6  probably 
due  to  the  better  diagnostic  criteria  employed, 
increased  age  of  population  and    widespread  and 
successful use of drug combination in cancer patients. 
A  comprehensive  review  of  reported 
myelodysplasia  and  acute  myeloid  leukemia 
cluded  that  up  to  10%  of 
Hodgkin’s lymphoma 
(NHL)  using  either  conventional  dose  alkylating 
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MDS  or  AML  within  a  decade  of  primary  therapy.
7 
Based  on  these  data  the  risk  of  therapy-related 
MDS/AML is an important consideration in the initial 
choice of therapy in these conditions. 
In  this  review  we  have  summarized  the  possible 
mechanisms  of  leukemogenesis,  analyzed  studies 
conducted  to  delineate  the  incidence  of  secondary 
MDS/AML  in  patients  with  CLL  and  WM  and 
discussed  the  potential  relationship  between  these 
events and treatment with NA and alkylating agents. 
 
Drugs Inducing Secondary Myeloid Neoplasms and 
Mechanism  of  Leukemogenesis:  Important 
discoveries have been made over recent years that have 
contributed  to  a  better  understanding  of  the 
pathogenesis  of    neoplasm  and  in  particular  of 
secondary  AML/MDS.  There  are  several  lines  of 
evidence showing that different mechanisms cooperate 
in leukemogenesis defining a  multistep process.  
Disease  related  immunodeficiency,  resulting  from 
both  cell  mediated  and  humoral-mediated  immunity 
defects, has been postulated as a possible mechanism 
predisposing  to  second  cancers  in  non  Hodgkin 
lymphoma (NHL) and in particular in CLL and WM 
patients. B-cell impairment, low gammaglobulin levels 
and  quantitative  and  functional  defects  of  various 
subsets  of  T  cells  have  all  been  documented  in 
lymphoprolipherative  diseases  and  are  implicated  in 
defective  immune  surveillance  favouring  second 
cancers. In line with this hypothesis is the documented 
incremented  occurrence  of  malignant  tumours  in 
patients  having  a  background  of  humoral 
immunodeficiency or abnormalities in T-cell function 
such  as  common  variable  immunodeficiency,  ataxia-
telangectasia,  HIV  disease.
8,9  Furthermore,  some 
authors  underline  the  crucial  role  of  the  immune 
system in the oncogenesis reporting an increased risk 
of  second  cancers  also  in  untreated  CLL  and  WM 
patients.
10,11 
However,  several  studies  have  raised  concerns 
about the role of therapy in the development of second 
malignancies and t-MN are a well recognized distinct 
entity  in  the  2008  WHO  classification  of  tumors  of  
hematopoietic and lymphoid tissues.
12 
Cytotoxic agents associated with this complication 
include alkylating agents, topoisomerase II inhibitors, 
ionizing  radiation,  antimetabolites  and  antitubulin 
agents.
12,13 The WHO classification considers therapy-
related MDS/AML as a unique clinical syndrome even 
though some  cases may satisfy the morphological or 
cytogenetic criteria for other entities. Indeed, particular 
cytotoxic  agents  are  associated  with  therapy-related 
MDS/AML with characteristic biological and clinical 
features. 
Alkylating  agents  damage  DNA  either  by 
methylation or DNA inter-strand crosslink formation. 
The latency between treatment and t-MN is generally 
long, between 5 and 7 years and  may be preceded by a 
myelodysplastic phase. Most cases present deletion or 
loss of the long arm or total loss of chromosome 5 (5q-
/-5) and/or deletion or loss of the long arm or total loss 
of chromosome 7 (7q-/-7).
14-16 
Topoisomerase  II  is  an  essential  enzyme  in 
eukaryotic  cells  and  is  thought  to  play  an  important 
role in DNA replication, transcription and cell division. 
This enzyme  catalyzes  the  breaking and  rejoining of 
both DNA strands. Topoisomerase II inhibitors block 
the enzymatic reaction through relegation and enzyme 
release,  leaving  the  DNA  with  a  permanent  strand 
break. Multiple DNA-strand breaks lead to cell death.  
Both  the  antineoplastic  effect  and  the  leukemogenic 
effect  are  due  to  chromosomal  break-age  and  this 
breakage,  resolved  by  chromosomal  translocation,  is 
the cause of the leukaemic transformation. A shorter 
latency of approximately  2 years  characterized t-MN 
secondary  to    topoisomerase  II  inhibitors.  Balanced 
chromosome  translocations  frequently  reported  after 
exposure  to  this  chemotherapeutic  agents    involve 
11q23  (MLL)  or  21q22  (RUNX1).  However,  others 
may also occur, for example t(8;21) or t(15;17) in the 
case of therapy-related acute promyelocytic leukemia 
(t-APL).
12,17,18 
Antimetabolites  share  structural  similarities  with 
nucleotides,  and  can  be  incorporated  into  DNA  or 
RNA, causing inhibition of cell proliferation. Among 
antimetabolite  agents  fludarabine  is  the  nucleoside 
analogs (NA) more frequently used in the treatment of 
indolent  lymphoproliferative  disorders[].
19  The 
combination of fludarabine with cyclophosphamide or 
other DNA damaging agents may increase the risk of 
MDS/AML due to synergistic effects in the ability to 
produce  DNA  damage.  Fludarabine  inhibits  DNA 
repair  and  augments  the  cytotoxic  effect  of  DNA 
damaging  agents  such  as  cyclophosphamide.
20  This 
enhancement of DNA damage may also affect marrow 
progenitor cells. Such a mechanism could explain the 
observed  impairment  of  peripheral  blood  progenitor 
cell  collection  after  prior  fludarabine  treatment  and 
could predispose to an increased risk of therapy-related 
MDS/AML.
21  High  occurrence  of  abnormalities  of 
chromosome  5  and  7  has  also  been  described    in 
MDS/AML secondary to NA therapy.
22-24 
In addition to typical genetic abnormalities, t-MN are 
characterized  by  molecular  changes  which  may 
cooperate in the pathogenesis of the disease. FLT3 and 
p53  mutations  are  the  most  frequent  described. 
Chimeric  rearrangement  of  transcription  factors, 
including AML1, CBFB, MLL or RARA and NPM1 
mutations have also been reported.
25 
An  important  role  in  the  multistep  secondary
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Table 1. MDS/AML occurrence in WM patients treated with alkylating agents 
Authors  N° of patients  MDS/AML (N,%) 
Facon 1993
29  167  2 (1.2%) 
Kyle 2000
30  46  3 (6.5%) 
Garcia Sanz 2001
31  217  3 (1.4%) 
Leblond 2001
32  46  2 (4.3%) 
Ghobrial 2006
33  337  16 (4.7%) 
Leleu 2009
34  136  0 
 
leukemogenesis has been recently attributed to the 
epigenetic  changes.  Epigenetic  mechanisms  such  as 
DNA  methylation,  post-translational  modifications  of 
histone proteins and remodelling of nucleosomes affect 
chromatin structure and contribute to define heritable 
changes in gene expression. The abnormalities in DNA 
methylation  profile  have  been  described  more 
commonly  in  therapy-related  rather  than  de  novo 
MDS/AML.
26 
Since only a small fraction of patients exposed to 
cytotoxic  therapy  developed  t-MN,  one  of  the 
important  questions  in  the  field  is  what  predisposes 
individuals to develop the disease. A large number of 
studies  have  offered  evidence  demonstrating  the 
importance  of  genetic  variation  in  key  genes,  which 
include those involved in drug metabolism, protection 
of  cellular  entities  from  damage  and  repair  of  DNA 
damage. Mutations in these vital genes are rare while 
much  more  common  are  genetic  polymorphisms  in 
detoxification  genes  and  in  genes  belonging  to  the 
major DNA repair pathways.
18 
Although the multistep leukemogenesis mechanism 
has  not  been  completely  clarified,  the  important 
knowledge achieved in the last years in this matter has 
laid  the  groundwork  to  a  risk  adapted  therapeutic 
approach.  An  adequate  screening  of  individual 
susceptibility to develop t-MN could influence initial 
treatment  strategies  with  the  goal  of  decreasing  the 
incidence of these serious complications.  
 
Waldenstrom  Macroglobulinemia:  WM  patients 
have  a  well  documented  increased  risk  of  second 
cancers  and  in  particular  of  secondary  MDS/AML. 
Although disease-related immune-suppression has been 
suggested as one of the main causes of this increasing 
risk,
10 the role of therapy in this important matter is 
under investigation.  
Several studies have been conducted in Europe and 
in  the  United  States  to  retrospectively  examine  the 
incidence  of  secondary  MDS/AML  in  treated  WM 
patients. 
Alkylating agents and NA such as fludarabine and 
2-chlorodeoxyadenosine  (2-CdA)  have  been 
considered    appropriate  first  line  agents  for  the 
treatment of WM.
27-28 
Among  patients  receiving  alkylating  agents  the 
incidence of such events ranged from 0 to 6% (Table 
1) in different retrospective studies.
29-33 Among them 
the  most  consistent  data  have  been  published  by 
Ghobrial et al
33 on 337 patients  with newly diagnosed  
symptomatic WM. After a median duration of follow  
up of 11 years death occurred in 237 (70%) patients. 
The cause of death was due to WM or complications of 
therapy in 125 cases (37%) cases. Of these, death due 
to  MDS/AML  occurred  in  16  patients  (4.7%) 
indicating that this is a serious and fatal complication 
of alkylating agents therapy. 
More recently attention has been focused on long 
term  toxicity  of  NA-based  therapy
34,35  and 
retrospective  comparative  data  has  been  reported  by 
the French Cooperative Group on CLL/WM
36 and by 
the Dana-Farber Cancer Institute.
37 
Leblond et al
36 reviewed the incidence of secondary 
MDS/AML  in  165  WM  patients  treated  with  NA 
agents in 3 trials performed from 1993 to 2003 by the 
French Cooperative Group on CLL/WM. 
In  the  first  trial
38  71  relapsed/refractory  WM 
patients  initially  treated  with  alkylating  agents  
received fludarabine. In the second trial
32 92 patients in 
first relapse after alkylating agents were randomized to 
receive  fludarabine  and  CAP  regimen  (doxorubicine, 
cyclophosphamide, prednisone). In the third trial
39 49 
patients with untreated or pretreated disease received 
fludarabine combined with cyclophosphamide.  
The  crude  incidence  of  secondary  MDS/AML 
varied  from  1.4  to  8.9%  in  patients  treated  with 
fludarabine alone and was 6% in patients treated with 
fludarabine  combined  with  cyclophosphamide. 
Incidence of such events were not different in the two 
groups of patients. More recently Leleu et al
37 carried 
out a retrospective study to delineate the incidence of 
secondary MDS/AML in a large population of patients 
with WM and to determine the potential relationship 
between these events and treatment with NA. Among 
the 439 consecutive patients considered in this study 
329 were treated with (193) or without (136) NA and 
110 patients remained untreated.  The median follow-
up  for  all  patients  was  5  years.  Overall  3  patients Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
(1.6%)  developed  secondary  MDS/AML  among  NA 
treated patients while no events were reported in both 
patients receiving other chemotherapeutic drugs and in 
untreated  patients    The  15-year  probabilities  of 
developing  secondary  MDS/AML  were  8%.    These 
data demonstrate an increased incidence of developing 
secondary  MDS/AML  among  patients  with  WM 
treated with NA. The incidence of MDS/AML was not 
statistically different in patients treated with NA as first 
line  treatment  versus  patients  treated  later  in  their 
disease history, in patients treated with either one or 
with  multiple  courses  of  NA,  and  in  patients  with 
history  versus  no  history  of  treatment  with  an  oral 
alkylating  agent.  Among  the  three  patients  who 
developed MDS/AML in this series, only one patient 
had previously received oral alkylating agents therapy. 
Furthermore,  none  of  the  clinical  and  laboratory 
features  studied  (gender,  age,  family  history  of 
haematological  malignancies,  markers  of  tumor 
burden,  prognosis  markers  including  WM-ISS) 
significantly predicted  the occurrence of  secondary 
MDS/AML  events.  However,  no  definite  conclusion 
can be drawn because of the low number of events and 
therefore a lack of power in multivariate analysis might 
also explain that no risk factors except treatment with 
NA were observed.  
Data  reported  in  all  these  retrospective  studies 
(Table 2) lead to conclude that although a role of NA 
in leukemogenesis has been wide recognized other data 
and  prospective  studies  are  needed  to  clarify    the 
impact of fludarabine and alkylating agent combination 
compared to fludarabine alone in the increased risk of  
t-MN in WM patients. 
In the last decade the use of rituximab has also been 
extensively  evaluated  in  patients  with  WM  and  high 
activity of fludarabine and rituximab combination with 
or without cyclophosphamide has been demonstrated.  
Treon et al
40 reported the long term outcome of a 
multicenter  prospective  study  examining  fludarabine 
and rituximab association in 43 WM patients with less 
than two prior therapies. With a median follow-up of 
40.3  months,  3  patients  (7%)  developed  myeloid 
malignancies: MDS in one case and AML in two cases. 
Among them one had previously received chlorambucil 
and  another  had  previously  undergone  high-dose 
chemotherapy with an autologous transplantation. The 
median  time  from  protocol  therapy  to  secondary 
MDS/AML was 39.4 months.   
More  recently  toxicities  data  of  fludarabine, 
cyclophosphamide  and  rituximab  combination  (FCR) 
have  been  reported  by  Leblond  et  al
41  in  55  WM 
patients. Among them 40  had been previously  treated 
with  a  median  of  2  lines  of  therapy  (range  1-4), 
including  24  patients  with  relapsed  disease  and  16 
patients with refractory disease. After a median follow-
up of 28 months secondary MDS/AML were observed 
in two heavily treated patients (3.6%).  Similar results 
have been observed by Tedeschi et al in a group of 43 
untreated  and    pretreated  patients  receiving  FCR 
schedule: MDS occurred in three patients (6.9%), all of 
them  previously  heavily  pretreated  with  alkylating 
agents,  after  5,  24  and  60  months  from  FCR, 
respectively.
42  Based  on  these  data,  addition  of 
rituximab to fludarabine containing regimens does not 
seem to increase the incidence of t-MN (Table 2). 
Although  data  on  fludarabine  treatment  are  more 
consistent,  recent analysis of long term toxicity after 
2-CdA therapy has also been  published.  
The  MD  Anderson  Cancer  Center  performed  a 
retrospective
  analysis  of  111  consecutive,  previously 
untreated patients with
 symptomatic WM who received 
2 consecutive 4–6-week
 courses of either 2-CdA alone 
or  in  combination  with  other  agents
  including 
prednisone,  cyclophosphamide,  and  rituximab. 
Thirteen  patients  (12%)  developed  second 
malignancies,  among  them  one  patient  had  AML 
(0.9%). The median time to development
 of a second 
malignancy was 85.5 months.
43 
Laszlo  et  al
44  recently  reported  the  results  with 
2CdA and rituximab combination in 29 WM patients in 
first  line  therapy  or  previously  treated  without  NA. 
With a median follow-up of 43 months no secondary 
MDS/AML was observed.  
 
Chronic  Lymphocytic  Leukemia:  Second 
malignancies  are  frequent  complications  in  patients 
with  CLL.  The  most  frequent  event  is  CLL 
transformation  to  large  B-cell  non-Hodgkin’s 
lymphoma  also  known  as  Richter’s  syndrome.
45-47 
However,  the  secondary  development  of 
myeloproliferative  disorders  as  well  as  solid  tumors 
has also been documented in CLL patients.
48,49 
An increased incidence of these late complications 
has   occasionally been reported  in  patients receiving 
alkylating  agents.  However,  occurrence  of  therapy-
related MDS/AML after exposure to alkylating agents 
seems to be lower when they are used intermittently as 
opposed to prolonged, continuous exposure.
50 
The  study  of  French  Cooperative  Group  on  CLL 
reported data of two randomized trials in 1535 patients 
with previously untreated stage A CLL.
50 In the first 
trial, 609 patients were randomly assigned to receive 
either daily chlorambucil or no treatment; in the second 
trial, 926 patients were randomly assigned to receive 
either intermittent chlorambucil plus prednisone or no 
treatment. Median follow-up for the first and second 
trials  exceeded  11  and  6  years,  respectively.  CLL 
patients receiving either intermittent chlorambucil and 
prednisone  or  no  treatment  showed  no  increase  of 
second  tumors;  in  particular  AML  was  observed  in
 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Table 2. MDS/AML occurrence in WM patients treated with fludarabine–based regimens. 
Authors  Prospective 
study  N° pts  pretreated  schedule  Median follow-up 
time from study  MDS/AML (N,%) 
Leblond 
1998
38  no   
71 
 
yes 
 
F 25 mg/m2 d1-5 
 
 
34 mo 
 
1/71 (1.4%) 
Leblond 
2001
32  yes 
45 
 
45 
yes 
F 25 mg/m2 d1-5 
 
Doxo 25 mg/m2 d1 
CTX 750 mg/m2 d1 
PDN 40 mg/m2 d1-5 
34 mo 
4/45 (8.9%) 
 
 
2/45 (4.5%) 
Tamburin
i 2005
39  no  49  35 pts 
 
F 30 mg/m2 d1-3 
CTX 300 mg/m2 d1-3 
 
43 mo  3/49 (6%) 
Leleu  
2009
37  no  439  na 
NA 
 
no NA 
 
untreated 
5 y 
3/193 (1.6%) 
 
0/136 
 
0/110 
Treon  
2009
40  yes  43  17 yes 
 
R 375 mg/m2/wk x 8 wks 
along with 
F 25 mg/m2/d x 5d x 6 cycles 
 
40.3 mo  3 (7%) 
Leblond  
2010
41  no  55  40 pts 
F 40 mg/m2 os d1-3 
CTX 250 mg/m2 os d1-3 
R 375 mg/m2 d1 
28 mo  2/55 (3.6%) 
Tedeschi 
2011
42  yes  43  15 pts 
 
F 25 mg/m2 d2-4 
CTX 250 mg/m2 d2-4 
R 375 mg/m2 d1 
 
38.8 mo  3 (6.9%) 
Rakkhit 
2008
43  no  111  no 
2CdA 0.1 mg/kg/d iv d1-7 
+/- 
PDN 60 mg/m2/d os d1-7 
 
2CdA 1.5 mg/m2 sc x 3/d d1-5 
+ CTX 40 mg/m2 os x 2/d d1-7 
+/- 
R 375 mg/m2/wk iv x 4 wks 
55 mo  1 (0.9%) 
Laszlo 
2010
44  yes  29  13 pts  2CdA 0.1 mg/kg/d sc d1-5 
R 375 mg/m2 d1  43 mo  0 
F=fludarabine;  Doxo=doxorubicin;  CTX=  cyclophosphamide;  PDN=  prednisone;  NA=  nucleoside  analogs;  R=  rituximab;  2CdA=  2-
chlorodeoxyadenosine; mo=months; y= years; wk= week; d=day; os= oral; na= not applicable 
 
only one case (0.2%). However, a higher frequency of 
second cancers was reported in the group of patients 
treated with daily chlorambucil and AML occurred in 4  
cases (1.3%). 
No  evidence  of  an  increased  risk  of  secondary 
MDS/AML  was  reported  at  M.D  Anderson  Cancer 
Center in a retrospective analysis of 1374 consecutive 
CLL  patients,  even  though  nearly  three  quarters  of 
these  patients  had  received  prior  treatment  with 
alkylating  agents.
51  Authors  suggest  that  the 
suppressive  properties  of  disease–related  cytokines 
acting on myeloid clones may be responsible for the 
lack of an increased rate of secondary AML/MDS in 
CLL  despite  prolonged  treatment  with  alkylating 
agents and disease related immunosuppression.  
In  contrast  to  the  published  experience  with 
alkylating  agents,  secondary  MDS/AML  are  rarely 
reported  following  NA  as  monotherapy  in  CLL 
patients.
52-56  However,  the  combination  of  NA  with 
alkylating agents or other DNA damaging agents may 
increase the t-MN risk due to their synergistic effects 
(Table 3).   
Morrison et al. presented data from intergroup CLL 
treatment trial comparing treatment with chlorambucil, 
fludarabine or chlorambucil plus fludarabine, in which 
a possible increase in the number of cases of therapy-
 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Table 3. MDS/AML occurrence in CLL patients treated with NA–based regimens 
Authors  Prospective 
study  N° pts  pretreated  schedule  Median follow-up time 
from study 
MDS/AML 
(N,%) 
Keating  
1998
52  yes  174  no 
 
F 25-30 mg/m2/d d1-5 
 
F 30 mg/m2/d d1-5 + 
PDN 30 mg/m2/d d1-5 
 
F 30 mg/m2/d d1-5 
 
98 mo 
 
62 mo 
 
 
39 mo 
0 
Leporrier  
2001
53  yes  924  no 
 
FAMP 25 mg/m2 d1-5 
vs 
CAP 
vs 
CHOP 
 
70 mo  0 
Johnson  
1996
54  yes  196  96 pts 
F 25 mg/m2 d1-5 
vs 
CAP 
34 mo  0 
 
 
Cheson 
1999
55 
no  724 
 
yes 
 
F 25 mg/m2/d d1-5  7.4  y  0 
Morrison 
2002
57  yes  544  no 
F 25 mg/m2  d1-5 
vs 
CHL 40 mg/m2 d1 
vs 
F 10-20 mg/m2 d1-5 + CHL 
15-20  mg/m2 d1 
4.2 y 
1/188(0.5%) 
 
0 
 
5/142 (3.5%) 
Smith 
2010
58  yes  278  no 
 
F 20 mg/m2 d1-5 + 
CTX 600 mg/m2 x d1 
vs 
F 25 mg/m2 d1-5 
 
6.4 y 
9/141 (6%) 
 
4/137 (3%) 
Robak  
2004
45  no  1487  no 
2CdA 0.12 mg/k/d d1-5 
Alkylating agents: CHL, 
CHOP, COP 
2CdA + Alkylating agents 
2.6 y 
3.3 y 
4.4 y 
0 
Badoux 
2011
59  yes  284  yes 
 
F  25mg/m2
  d1/2-3/4 
CTX 250mg/m2 d1/2-3/4 
R 375-500mg/m2 d1 
 
43 mo  9 (3%) 
Tam 
2008
4  yes  224  no 
F  25mg/m2
  d1/2-3/4 
CTX 250mg/m2 d1/2-3/4 
R 375-500mg/m2 d1 
6 y  8 (2.8%) 
Woyach 
2011
60  yes  104  no 
 
F  25mg/m2
  d1-5 q4w x 6 
cycles followed by 
R 375 mg/m2 x 4 doses 
vs 
F  25mg/m2 d1-5 + 
R 375 mg/m2 d1 followed by 
R 375 mg/m2
 /wk x 4 doses 
117 mo  0 
F=fludarabine;  Doxo=doxorubicin;  CTX=  cyclophosphamide;  PDN=  prednisone;  NA=  nucleoside  analogs;  R=  rituximab;  2CdA=  2-
chlorodeoxyadenosine; CHL= chlorambucil; CAP= doxorubicine, cyclophosphamide, prednisone; COP= cyclophosphamide, prednisone, 
vincristine; CHOP=  doxorubicine, cyclophosphamide, prednisone, vincristine; mo=months; y= years; wk= week; d=day. 
 
related AML was observed.
57 With a median follow-up 
of  4.2  years,  six  patients  (1.2%)  developed  therapy-
related MDS or MDS evolving to AML, from 27 to 53 
months after study entry. This includes five (3.5%) of 
142 patients treated with chlorambucil plus fludarabine 
and  one  (0.5%)  of  188  receiving  fludarabine.  In  the 
group treated with chlorambucil alone MDS or AML 
were not  observed.  These findings  may  indicate that 
alkylating agents combined with NA may increase the 
risk of therapy-related MDS/AML in CLL patients.  Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
These  data  have  been  recently  confirmed  by  the 
prospective  randomized  phase  3  trial,  E2997, 
comparing FC with F alone as initial therapy in 278 
CLL patients. With a median follow-up of 6.4 years, 
there have been 13 cases of t-MN, 9 cases after FC and 
4 after fludarabine alone. The increased incidence of t-
MN  after  FC,  usually  in  the  absence    of  additional 
treatment, suggests that FC is more leukemogenic than 
fludarabine.
58 
In contrast Robak et al.
45 did not observed any MDS 
or AML in a retrospective series of  1487 CLL patients 
treated with 2-CdA, alkylating agents or both.  
In  the  last  five  years  chemoimmunotherapy 
regimens including rituximab showed high activity in 
CLL  patients  improving  quality  and  duration  of 
responses.    The  chemoimmunotherapy  FCR  has 
become  a  standard  treatment  for  CLL  based  on  the 
German CLL Study Group (GCLLSG) frontline CLL8 
trial and the International REACH trial for patients in 
first relapse.
1,2 
Data  of  long  term  follow-up  of  FCR-therapy  has 
been  published by Badoux  et al
59 in  a  group of 284 
previously treated patients followed in M. D. Anderson 
Cancer  Center.  Among  them  nine  patients  (3%) 
developed  secondary  MDS  or  AML  (n=1)  with  a 
median of 20 months from starting FCR. Eight of these 
nine patients died after a median OS time of 23 months 
from FCR therapy. Comparable data has been reported 
by the same group
4 with first-line FCR therapy: after a 
median  follow-up    of  6  years  MDS  occurred  during 
first remission  in  8  of 224  patients (2.8%)  receiving 
immunochemotherapy.  
More  recently  results  published  by  Cancer  and 
Leukemia Group Study
60 suggest that incidence of t-
MN  does  not  increase  with  Fludarabine-rituximab 
combination (FR) without cyclophosphamide. After a 
median follow-up  of   117  months  none  of  untreated 
patients receiving fludarabine-rituximab concurrent or 
sequential  combination  developed  t-MN  during 
remission.  Only  one  patient  experienced  therapy-
related MDS, however, this occurred 45 months after 
FR treatment and 9 months after salvage treatment with 
FCR combination.  
Studies  examining  consolidative  autologous  stem 
cell  transplantation  in  CLL  have  also  reported  an 
increased risk of t-MN. Gribben et al identified in the 
Dana  Farber  series,    an  actuarial  incidence  of 
MDS/AML  of  12%  at  8  years.
61  The  137  patients 
considered in this series received conditioning regimen 
with  cyclophosphamide  and  total  body  irradiation. 
Previous  debulking  therapy  consisted  of  alkylating 
agents and/or fludarabine and/or rituximab.   
A  lower  incidence  of  secondary  MDS/AML  was 
reported by the German CLL-3 trial with three cases in 
150 patients who underwent autograft.
62 
As well as the Dana Farber group a high occurrence 
of MDS/AML has also been described by  Milligan et 
al in patients enrolled in the Medical Research Council 
Chronic  Lymphocytic  Leukaemia-5  trial.
63  Of  115 
newly diagnosed patients treated with fludarabine, 65 
patients  proceeded  to  autologous  transplant. 
Conditioning  was  cyclophosphamide  and  total  body 
irradiation in 49 (75%) patients and chemotherapy in 
12  (18%).  Ten  patients  developed  MDS/AML;  eight 
had undergone an autograft. Risk of MDS/AML was 
not  associated  with  type  of  prior  therapy.  Five-year 
actuarial risk of developing MDS/AML postautograft 
was  12.4%.  No  analysed  potential  risk  factor  was 
predictive  for  MDS/AML  development.  Authors 
hypothesise  that  potential  causative  factors  are 
fludarabine, low cell dose and transplant conditioning. 
The  UK  and  German  data  differ  in  that  there  is  an 
increased exposure to fludarabine and a lower infused 
cell  dose  in  the  UK.  It  has  been  suggested  that  the 
relatively low cell dose infused permitted a preferential 
expansion of damaged residual host stem cells, and that 
the  myeloablative  conditioning  treatment  will  not 
destroy  all  hematopoietic  cells  with  proliferative 
potential.  
Recently results published of a phase 3 randomized 
trial  of  autografting  in  CLL  versus  observation  for 
responding patients after first or second line treatment 
reported MDS in 4 patients: 3 in the autografiting arm 
(2.7%)  and  1  in  the  observation  arm  (0.9%).  The 
relatively  low  occurrence  of  MDS  in  the 
autotransplantation arm may be related to the limited 
follow-up of 5 years after randomization.
64 
 
Conclusions:  The  increased  risk  of  secondary 
malignancies  occurring  in  WM  and  CLL  patients  is 
well documented.  
Overall  published  data  reported  frequently  higher 
occurrence  of  t-MN  in  WM  rather  than  in  CLL 
patients,  while  in  CLL  patients  transformation  to 
Richter’s syndrome or the evolution to prolymphocytic 
leukemia is the more frequent long term complication.  
The complex immunodeficiency resulting from B-
cell  impairment,  hypogammaglobulinemia,  T-cell 
dysfunction  and  decreased natural  killer-cell  activity, 
associated with these diseases may play a crucial role 
in  leukemogenesis.  However,  there is   great concern 
that  therapy,  especially  with  alkylating  agents  and 
purine  nucleoside  analogs,  may  further  contribute  to 
increase the risk of this devastating complication.  
Although in the last few years several retrospective 
studies  have  been  published  on  this  topic,  the  real 
impact on risk of secondary  MDS/AML complication 
of  the  single  therapeutic  agents  has  not  been  
definitively clarified. 
Indeed  assessment  of  the  specific  risk  is  often Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
confounded  in  patients  with  indolent 
lymphoprolipherative diseases by frequent exposure to 
multiple lines of cytotoxic therapy. Rates of secondary 
myeloid  malignancies  also  vary  with  the  length  of 
follow-up and  estimation may be falsely high if early 
reversible dysplastic features and cytopenia associated 
with cytotoxic treatment are misinterpreted. 
Furthermore,  the  role  played  by  additional 
immunosuppression  due  to  the  introduction  of 
monoclonal antibodies in clinical practice needs to be 
better understood.       
These  considerations  lead  to  conclude  that  the 
impact  of  secondary  MDS/AML  and  the  role  of  old 
and  new  drugs  in  the  development  of  these  late 
complications  needs  to  be  better  evaluated  in  larger 
prospective  studies,  especially  in  young  patients.  In 
view of these data, we suggest that risk versus benefit 
should be considered when treating younger WM and 
CLL patients. 
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